Melanotan II vs PT-141: Melanocortin Peptide Comparison

Melanotan II (MT-II) is a synthetic cyclic peptide with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. By activating MC1R on melanocytes, it stimulates the production and dispersal of melanin, producing a progressive darkening of skin pigmentation that occurs over days to weeks of administration. This tanning effect does not require UV exposure, though concurrent sun exposure accelerates and deepens the response. The tanning produced by Melanotan II has been of interest for its potential to provide a degree of photoprotection against UV radiation.

Beyond its melanogenic effects, Melanotan II's non-selective melanocortin receptor activation produces several concurrent physiological responses. Activation of MC3R and MC4R in the hypothalamus produces sexual arousal effects, including increased erectile function in men and genital arousal in women. MC4R activation also produces appetite suppression, which has been documented in clinical studies as reduced food intake and mild weight loss. Some users also report increased energy and mood elevation, effects that may be related to central melanocortin system activation.

Melanotan II has never received regulatory approval for any indication and remains an unregistered research compound in most jurisdictions. Despite this, it has developed a significant underground market, particularly among individuals seeking enhanced tanning. Health authorities in multiple countries have issued warnings about Melanotan II due to concerns about unregulated product quality, the risks of non-selective melanocortin activation, and reports of adverse effects including nausea, facial flushing, changes to existing moles, and rare cases of melanoma activation in susceptible individuals.

PT-141 (bremelanotide) was developed through metabolic modification of Melanotan II, resulting in a cyclic heptapeptide with preferential activity at MC3R and MC4R—the melanocortin receptor subtypes most directly involved in sexual function. By shifting the activity profile away from MC1R, PT-141 produces sexual arousal effects with significantly less impact on skin pigmentation compared to Melanotan II. Its mechanism of action is unique among sexual dysfunction treatments: rather than acting on peripheral vascular mechanisms (like PDE5 inhibitors such as sildenafil) or hormonal pathways, PT-141 acts centrally in the hypothalamus to increase sexual desire and arousal.

PT-141 received FDA approval in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval was based on two Phase 3 clinical trials (RECONNECT) demonstrating statistically significant improvements in sexual desire and reductions in distress related to low sexual desire. Vyleesi is administered as a subcutaneous injection in the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a recommended limit of no more than one dose per 24 hours and no more than 8 doses per month.

The clinical development of PT-141 for male erectile dysfunction also yielded positive results in Phase 2 trials, demonstrating efficacy in men who did not respond to PDE5 inhibitors. However, development for this indication was not continued to Phase 3. Common side effects of PT-141 include nausea (approximately 40% of patients), flushing, headache, and injection site reactions. The nausea is the most limiting side effect and tends to be more pronounced with the first few doses. A notable advantage of PT-141 is that it works through desire and arousal pathways rather than mechanical erectile mechanisms, potentially offering benefit to patients with psychogenic or centrally-mediated sexual dysfunction.